News

Major $70 Million Royalty Deal by MacroGenics and Sagard

Major $70 Million Royalty Deal by MacroGenics and Sagard

MacroGenics Partners with Sagard for Royalty Acquisition

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company dedicated to advancing innovative cancer therapeutics, has established a significant royalty purchase agreement with Sagard Healthcare Partners. This partnership involves a substantial upfront cash injection of $70 million, providing a notable boost to MacroGenics' financial resources and enhancing its capacity to continue its development efforts.

This agreement revolves around a capped royalty interest on the future net sales of ZYNYZ (retifanlimab-dlwr), a pivotal drug in MacroGenics' portfolio. Originally developed by MacroGenics, ZYNYZ is a PD-1 inhibitor that has been licensed to Incyte, following an exclusive collaboration that was initiated in 2017. Through this agreement, MacroGenics retains important economic interests related to ZYNYZ, including potential milestone payments from future development and regulatory progress.

Financial Impact and Future Outlook

With the immediate benefit of the $70 million upfront payment, MacroGenics is poised to extend its financial runway through the first half of 2027. The company reported having $154.1 million in cash and marketable securities as of March 31, 2025, which, combined with this new funding, is expected to support its ongoing clinical and preclinical programs. Additionally, the deal allows the company to benefit from future royalties once Sagard receives a total of $140 million in aggregate royalty payments.

Key Features of ZYNYZ

ZYNYZ has garnered attention as a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). It is currently indicated for use in combination with chemotherapy for the initial treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). ZYNYZ also serves as a single-agent treatment for adult patients who have progressed or experienced intolerance to previous chemotherapy options.

In addition to its SCAC indications, ZYNYZ is approved for treating adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the U.S. This approval, granted under accelerated conditions, emphasizes the necessity for further confirmatory trials to ensure the drug's continued market presence.

About MacroGenics

MacroGenics is a biopharmaceutical company committed to uncovering new therapy avenues for cancer through its innovative monoclonal antibody technology. The firm’s diverse pipeline of drug candidates is largely driven by its proprietary technology platforms, which are applicable across numerous therapeutic areas. Part of MacroGenics’ strength lies in their collaboration with global pharmaceutical and biotechnology partners, fostering innovation and development in the fight against cancer.

About Sagard Healthcare Partners

Sagard Healthcare Partners stands out as a multi-strategy asset management firm, managing assets exceeding $25 billion across various investment realms including venture capital, private equity, and real estate. With a robust team of over 400 professionals, Sagard aims to deliver flexible capital and create lasting partnerships, enhancing investment growth and innovation.

Frequently Asked Questions

What is the purpose of the royalty purchase agreement between MacroGenics and Sagard?

The agreement allows MacroGenics to gain a $70 million upfront cash injection, while granting Sagard a capped royalty interest on future net sales of ZYNYZ.

How does this agreement affect MacroGenics' financial situation?

With the $70 million received and existing cash, MacroGenics expects to extend its financial runway to support research and development initiatives into 2027.

What is ZYNYZ and how is it used in treatment?

ZYNYZ is a monoclonal antibody used in treating certain types of cancers such as SCAC and MCC, often in combination with other therapies.

What financial milestones are associated with this agreement?

Once Sagard receives $140 million from the royalties, MacroGenics will regain its right to collect all future royalty payments on ZYNYZ sales.

Where can I find more information about MacroGenics and their products?

For additional details on MacroGenics and their innovate therapies, visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 8

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Elah Holdings' Q3 2026 Report Sparks Investor Interest

Updated Category News Views 79

Elah Holdings Drops Their Q3 2026 Numbers Eat your heart out, folks—Elah Holdings has just dropped their third quarter report for 2026, and it caught some eyes. This ain't your run-of-the-mill, brush-right-past-it release. They're out there, waving their flag high in the competitive marketplace, trying to tell us they mean business. If you missed the announcement, they...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 101

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 10

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 99

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
ArcSpan AMS Nabs Top Honors at The Wires 2026

Updated Category News Views 159

ArcSpan Takes Center Stage with Prestigious Accolade ArcSpan just bagged the Best New Product or Service: Sell Side award at The Wires 2026. This ain't your average pat on the back. Taking place at the ritzy One Marylebone in London, this win springs from an event that celebrates the crème de la crème of digital advertising innovation. A Solid Win Amid The Changing Ad...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 229

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovation and Growth: The Future of CODiE Awards 2025

Updated Category News Views 206

The Exciting Future of the CODiE Awards The CODiE Awards, a prestigious program that shines a light on excellence in technology, is stepping into a thrilling new era. With a legacy spanning nearly 40 years, the CODiE Awards are set to expand in 2025, showcasing a wider array of groundbreaking technologies that are reshaping multiple industries, including tech products,...

Continue Reading
aTyr Pharma's Optimistic Trial Data Strengthens Market Position

Updated Category News Views 288

aTyr Pharma's Positive Trial Results Highlight Drug Potential aTyr Pharma (NASDAQ: ATYR) recently reaffirmed its Buy rating and set a price target of $22.00 amid encouraging trial data for its innovative treatment efzofitimod, targeting pulmonary sarcoidosis. This re-evaluation followed the release of a detailed post hoc analysis from its Phase 1/2a clinical trial, which...

Continue Reading
Precision Sapphire Wafers: Redefining Optical Coating Standards

Updated Category News Views 236

Introducing Ultra-Flat Sapphire Wafers for Optical Coating Meller Optics, Inc. has revolutionized the optical industry by launching a full line of optical-grade sapphire wafers. These wafers are fabricated through a proprietary process that ensures extreme flatness, a crucial requirement for high-quality optical applications. Exceptional Specifications of Sapphire Wafers...

Continue Reading
FHLB Dallas and First Security Bank Grant $30K to Local Charity

Updated Category News Views 138

FHLB Dallas and First Security Bank Collaborate to Aid Conway Ministry Center In a significant initiative aimed at community support, representatives from the Federal Home Loan Bank of Dallas (FHLB Dallas) and First Security Bank have come together to award an impressive $30,000 grant to the Conway Ministry Center. This generous funding is designated to enhance shelter...

Continue Reading
Exploring the Future of the Content Management System Market

Updated Category News Views 187

Growing Demand in the Content Management System Market The Content Management System market is witnessing a remarkable evolution, and this growth is driven largely by the increasing need for digital transformation within businesses across various industries. As of recent evaluations, the market size is projected to expand to USD 79.30 billion, following a growth rate of...

Continue Reading